acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Company profile
Ticker
TLPH
Exchange
Website
CEO
Vincent Angotti
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ACELRX PHARMACEUTICALS INC
SEC CIK
TLPH stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
6 Mar 24
8-K
Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update
6 Mar 24
8-K
Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
1 Mar 24
EFFECT
Notice of effectiveness
14 Feb 24
424B7
Prospectus with selling stockholder info
13 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
UPLOAD
Letter from SEC
9 Feb 24
S-3
Shelf registration
6 Feb 24
D
$6.00 mm in options / securities to be acquired, sold $6.00 mm, 6 investors
29 Jan 24
8-K
Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
22 Jan 24
Transcripts
TLPH
Earnings call transcript
2023 Q4
6 Mar 24
TLPH
Earnings call transcript
2023 Q3
8 Nov 23
TLPH
Earnings call transcript
2023 Q2
10 Aug 23
TLPH
Earnings call transcript
2023 Q2
10 Aug 23
TLPH
Earnings call transcript
2023 Q1
10 May 23
TLPH
Earnings call transcript
2022 Q4
30 Mar 23
TLPH
Earnings call transcript
2022 Q3
15 Nov 22
TLPH
Earnings call transcript
2022 Q2
12 Aug 22
TLPH
Earnings call transcript
2022 Q1
16 May 22
TLPH
Earnings call transcript
2021 Q4
11 Mar 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
30.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 28 |
Opened positions | 2 |
Closed positions | 7 |
Increased positions | 4 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 1.17 bn |
Total shares | 5.12 mm |
Total puts | 0.00 |
Total calls | 18.30 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BML Investment Partners | 4.06 mm | $7.64 mm |
Rock Springs Capital Management | 316.46 k | $351.27 mm |
Tang Capital Management | 195.00 k | $216.45 mm |
Vanguard | 157.51 k | $174.83 mm |
Values First Advisors | 122.44 k | $135.91 mm |
BLK Blackrock | 92.09 k | $102.22 mm |
Geode Capital Management | 68.90 k | $76.48 mm |
STT State Street | 22.18 k | $24.62 mm |
Texas Capital Bank Wealth Management Services | 21.50 k | $23.87 mm |
Susquehanna International | 16.66 k | $18.49 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Mar 24 | Nantahala Capital Management | 2024 Pre-Funded Warrants Common Stock | Other | Acquire J | Yes | No | 0.001 | 324,675 | 324.68 | 6,493,507 |
15 Mar 24 | Nantahala Capital Management | Common Stock | Acquire X | Yes | No | 5 | 755,000 | 3.78 mm | 1,992,519 | |
15 Mar 24 | Nantahala Capital Management | Put Option (obligation to buy) Common Stock | Dispose X | Yes | No | 5 | 755,000 | 3.78 mm | 0 | |
12 Mar 24 | Angotti Vincent J. | Common Stock | Grant | Acquire A | No | No | 1.1244 | 8,000 | 9.00 k | 170,806 |
11 Mar 24 | Angotti Vincent J. | Common Stock | Grant | Acquire A | No | No | 1.115 | 1,000 | 1.12 k | 162,806 |
3 Mar 24 | Badri N Dasu | Common Stock | Payment of exercise | Dispose F | No | No | 1.3 | 406 | 527.80 | 31,414 |
3 Mar 24 | Pamela P Palmer | Common Stock | Payment of exercise | Dispose F | No | No | 1.3 | 450 | 585.00 | 59,149 |
News
12 Health Care Stocks Moving In Monday's Pre-Market Session
11 Mar 24
12 Health Care Stocks Moving In Friday's After-Market Session
8 Mar 24
12 Health Care Stocks Moving In Thursday's After-Market Session
7 Mar 24
HC Wainwright & Co. Reiterates Buy on Talphera, Maintains $6 Price Target
7 Mar 24
Talphera Q4 EPS $(0.25) Misses $(0.20) Estimate, Sales $281.00K Beat $280.00K Estimate
6 Mar 24
Press releases
Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
1 Mar 24
Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
18 Jan 24
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
9 Jan 24